Literature DB >> 1962103

Endocarditis due to Corynebacterium pseudodiphtheriticum: five case reports, review, and antibiotic susceptibilities of nine strains.

A Morris1, I Guild.   

Abstract

Five cases of endocarditis due to Corynebacterium pseudodiphtheriticum are described. Two patients died, two patients with prosthetic valve endocarditis were successfully treated with antibiotics and valve replacement, and one patient with native valve endocarditis was successfully treated with penicillin alone. We also review 12 previously reported cases of C. pseudodiphtheriticum endocarditis. In vitro susceptibilities to 15 antibiotics were determined for nine isolates. The minimum inhibitory concentrations (MICs) of penicillin, amoxicillin, cefamandole, cephalexin, and rifampicin were all less than or equal to 0.12 mg/L. The MICs of vancomycin and ciprofloxacin for all strains were less than or equal to 0.5 mg/L. Tobramycin was the most active aminoglycoside, with MICs for all strains that were less than or equal to 0.12 mg/L. On the basis of in vitro data and the results of previous reports, penicillin alone or in combination with an aminoglycoside should achieve bacteriologic cure. Vancomycin should be used in patients who are allergic to penicillin.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1962103     DOI: 10.1093/clinids/13.5.887

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  12 in total

1.  Corynebacterium pseudodiphtheriticum: Putative probiotic, opportunistic infector, emerging pathogen.

Authors:  Andreas Burkovski
Journal:  Virulence       Date:  2015       Impact factor: 5.882

Review 2.  Native valve endocarditis due to Corynebacterium striatum.

Authors:  D N Juurlink; A Borczyk; A E Simor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

3.  Isolation of gram-positive rods that resemble but are clearly distinct from Actinomyces pyogenes from mixed wound infections.

Authors:  J Wüst; G M Lucchini; J Lüthy-Hottenstein; F Brun; M Altwegg
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

Review 4.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

5.  Non-diphtheriae Corynebacterium species are associated with decreased risk of pneumococcal colonization during infancy.

Authors:  Matthew S Kelly; Catherine Plunkett; Yahe Yu; Jhoanna N Aquino; Sweta M Patel; Jillian H Hurst; Rebecca R Young; Marek Smieja; Andrew P Steenhoff; Tonya Arscott-Mills; Kristen A Feemster; Sefelani Boiditswe; Tirayaone Leburu; Tiny Mazhani; Mohamed Z Patel; John F Rawls; Jayanth Jawahar; Samir S Shah; Christopher R Polage; Coleen K Cunningham; Patrick C Seed
Journal:  ISME J       Date:  2021-09-11       Impact factor: 10.302

6.  Prosthetic valve endocarditis caused by Corynebacterium afermentans subsp. lipophilum (CDC coryneform group ANF-1).

Authors:  D L Sewell; M B Coyle; G Funke
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

7.  Antimicrobial susceptibilities of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents.

Authors:  F Soriano; J Zapardiel; E Nieto
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 8.  Exudative pharyngitis possibly due to Corynebacterium pseudodiphtheriticum, a new challenge in the differential diagnosis of diphtheria.

Authors:  H S Izurieta; P M Strebel; T Youngblood; D G Hollis; T Popovic
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

9.  Corynebacterium endocarditis species-specific risk factors and outcomes.

Authors:  Jaime Belmares; Stephanie Detterline; Janet B Pak; Jorge P Parada
Journal:  BMC Infect Dis       Date:  2007-02-06       Impact factor: 3.090

10.  Importance of Coryneform Bacteria in Infective Endocarditis.

Authors:  Alexander von Graevenitz
Journal:  Infect Dis Rep       Date:  2015-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.